Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study

To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report clinical outcomes of 17 consecutive cases of...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2020-06, Vol.11, p.857
Main Authors: Giudice, Valentina, Pagliano, Pasquale, Vatrella, Alessandro, Masullo, Alfonso, Poto, Sergio, Polverino, Benedetto Maria, Gammaldi, Renato, Maglio, Angelantonio, Sellitto, Carmine, Vitale, Carolina, Serio, Bianca, Cuffa, Bianca, Borrelli, Anna, Vecchione, Carmine, Filippelli, Amelia, Selleri, Carmine
Format: Article
Language:English
Subjects:
Antibiotics
ARDS (acute respiratory distress syndrome)
Blood
Blood platelets
Chronic obstructive pulmonary disease
Clinical outcomes
Complement component C5a
COVID-19
Cytokines
Dehydrogenases
Disease prevention
Drug dosages
eculizumab
Hemoglobin
Immune response
Inflammation
Intensive care
JAK inhibitor
Janus kinase
Medical diagnosis
Monoclonal antibodies
Neutrophils
Permeability
Pharmacology
Pulmonary lesions
Respiratory distress syndrome
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Thrombosis
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!